Search Result

Results for "

Multi-target anticancer

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (8) Aurora Kinase (1) c-Fms (1) c-Kit (4) c-Met/HGFR (2) Carbonic Anhydrase (1) CDK (2) COX (1) EGFR (7) ERK (1) Estrogen Receptor/ERR (1) HCV (1) HCV Protease (1) HSP (1) Isotope-Labeled Compounds (1) MDM-2/p53 (2) Microtubule/Tubulin (1) Mitosis (1) Necroptosis (1) NO Synthase (3) PDGFR (1) PGE synthase (1) Pim (1) PKC (3) Raf (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) STAT (1) Topoisomerase (4) VEGFR (11)
By Research Areas:	Cancer (14) Infection (1) Neurological Disease (1)

By Targets:

Apoptosis (8)

Aurora Kinase (1)

c-Fms (1)

c-Kit (4)

c-Met/HGFR (2)

Carbonic Anhydrase (1)

CDK (2)

COX (1)

EGFR (7)

ERK (1)

Estrogen Receptor/ERR (1)

HCV (1)

HCV Protease (1)

HSP (1)

Isotope-Labeled Compounds (1)

MDM-2/p53 (2)

Microtubule/Tubulin (1)

Mitosis (1)

Necroptosis (1)

NO Synthase (3)

PDGFR (1)

PGE synthase (1)

Pim (1)

PKC (3)

Raf (1)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

STAT (1)

Topoisomerase (4)

VEGFR (11)

By Research Areas:

Cancer (14)

Infection (1)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10230

Midostaurin 35+ Cited Publications PKC412; CGP 41251	PKC VEGFR c-Kit NO Synthase Apoptosis	Cancer
Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

HY-124526

Chiauranib Ibcasertib; CS2164	PDGFR c-Fms Aurora Kinase VEGFR c-Kit Mitosis	Cancer
Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC₅₀ values ranging from 1-9 nM. Chiauranib has strongly anticancer effects .

HY-N12586

Pheophytin a	ERK Reactive Oxygen Species (ROS) COX PGE synthase STAT HCV HCV Protease	Infection Neurological Disease Cancer
Pheophytin a is a multi-target inhibitor, anticancer agent, antioxidant and antiviral agent. Pheophytin a directly binds to and inhibits HCV-NS3/4A protease (IC₅₀=0.89 μM) to block viral replication. Pheophytin a also scavenges free radicals, reduces ferric ions, and exhibits cytotoxic activity against breast cancer cells. Pheophytin a effectively inhibits LPS-induced production of nitric oxide, prostaglandin E2, NOS2 and COX-2, as well as various pro-inflammatory cytokines, by downregulating the transcription levels of inflammatory mediators and blocking the ERK1/2 and STAT-1 pathways. In a low nerve growth factor environment, Pheophytin a also enhances ERK1/2 phosphorylation and synergistically promotes neurite outgrowth through MAPK pathway. Pheophytin a can be used to investigate the pathogenic mechanisms of diseases including chronic hepatitis C, sepsis, breast cancer and Alzheimer's disease .

HY-146228

HSP90-IN-13	HSP Apoptosis Topoisomerase EGFR VEGFR	Cancer
HSP90-IN-13 (compound 5k) is a highly potent HSP90 pan inhibitor with an IC₅₀ value of 25.07 nM. HSP90-IN-13 has multi-target activity against EGFR, VEGFR-2 and Topoisomerase-2. HSP90-IN-13 causes cell cycle arrest at G2/M phase and induces apoptosis of MCF-7 cells through mitochondrial-mediated pathway .

HY-175171

Anticancer agent 276	Topoisomerase VEGFR c-Met/HGFR EGFR Estrogen Receptor/ERR	Cancer
Anticancer agent 276 (Compound 5) is a multi-target anticancer agent. Anticancer agent 276 has a potent anticancer activity against human tumor cells with IC₅₀s of 6.90 and 4.48 μM for HEPG2 and MCF7 cells, respectively. Anticancer agent 276 shows strong and stable interactions across multiple targets, including Topoisomerase II, VEGFR2, c-Met, EGFR and ERα .

HY-179098

Multi-target kinase-IN-8	Raf c-Met/HGFR Pim EGFR VEGFR Apoptosis	Cancer
Multi-target kinase-IN-8 (3d) is an anti-cancer agent. Multi-target kinase-IN-8 exhibits inhibitory activity against various protein kinases (B-Raf V600E (IC₅₀ = 0.078 µg/mL), c-Met (IC₅₀ = 0.405 µg/mL), Pim-1 (IC₅₀ = 1.053 µg/mL), EGFR WT (IC₅₀ = 0.177 µg/mL), VEGFR-2 (IC₅₀ = 0.275 µg/mL)). Multi-target kinase-IN-8 can induce cell cycle arrest and promote early and late apoptosis. Multi-target kinase-IN-8 is commonly used in cancer research .

HY-10230R

Midostaurin (Standard) PKC412 (Standard); CGP 41251 (Standard)	Reference Standards PKC VEGFR c-Kit NO Synthase Apoptosis	Cancer
Midostaurin (Standard) is the analytical standard of Midostaurin. This product is intended for research and analytical applications. Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

HY-169216

Multi-target kinase inhibitor 3	EGFR VEGFR CDK	Cancer
Multi-target kinase inhibitor 3 (compund 6i) is a multi-kinase target inhibitor with anticancer activity. Multi-target kinase inhibitor 3 inhibits EGFR, HER2, VEGFR-2, and CDK2 with IC50s of 0.063 μM, 0.054 μM, 0.119 μM, and 0.448 μM, respectively. Multi-target kinase inhibitor 3 has a good inhibitory effect on breast cancer cells MCF-7, with an IC50 of 6.10 μM .

HY-120520

Caylin-1	MDM-2/p53	Cancer
Caylin-1 is an inhibitor of MDM2 and an analog of Nutlin-3. Caylin-1 can bind to Bcl-XL and is used in multi-target anticancer research .

HY-163723

EGFR-IN-116	EGFR VEGFR Topoisomerase	Cancer
EGFR-IN-116 (compound 14D) is an anticancer agent. EGFR-IN-116 against EGFR has the IC₅₀ valuesof EGFR, VEGFR-2 and Topo II are 0.103 μM, 0.069 μM and 19.74 μM, respectively .

HY-W751179

Midostaurin-13C6 PKC412-¹³C₆; CGP 41251-¹³C₆	Isotope-Labeled Compounds Apoptosis VEGFR PKC c-Kit NO Synthase	Cancer
Midostaurin- ¹³C₆ (PKC412- ¹³C₆) is the ¹³C-labeled Midostaurin (HY-10230). Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

HY-149407

Multi-kinase-IN-4	VEGFR CDK EGFR Necroptosis Apoptosis	Cancer
Multi-kinase-IN-4 (compound 5d) is multi-targeted kinase inhibitor, including VEGFR2, EGFR, HER2, and CDK2, with IC₅₀ values of 0.33, 0.22, 0.18 and 2.09 μM, respectively. Multi-kinase-IN-4 shows broad-spectrum anti-cancer activities against HepG2, MCF-7, MDA-231, and HeLa cell lines (IC₅₀ = 1.94–7.1 µM), but exhibits lower toxicity in the WI-38 cells (IC₅₀ = 40.85 µM). Multi-kinase-IN-4 induces apoptosis and arrests cell cycle at S phase in HepG2 cells. Multi-kinase-IN-4 has the potential for the research of cancer .

HY-182245

Anticancer agent 314	Microtubule/Tubulin Carbonic Anhydrase Apoptosis MDM-2/p53	Cancer
Anticancer agent 314 is a multi-target anticancer agent with tubulin polymerization inhibitory activity (IC₅₀ = 6.35 μM) and human carbonic anhydrase IX (K_i = 27.1 nM) and XII (K_i 20.9 = nM) inhibitory activity. Anticancer agent 314 binds to the colchicine-binding pocket of tubulin and inhibits tumor-associated carbonic anhydrase isoforms via zinc coordination within enzyme active sites. Anticancer agent 314 induces G2/M phase cell cycle arrest, apoptosis via p53-dependent signaling, and broad-spectrum antiproliferative activity across multiple cancer cells. Anticancer agent 314 can be used for the research of cancer, such as leukemia, melanoma, ovarian cancer .

HY-183090

EGFR/VEGFR2-IN-13	VEGFR Apoptosis Topoisomerase EGFR	Cancer
EGFR/VEGFR2-IN-13 is a multi-target inhibitor, with an IC₅₀ of 0.98 µM against VEGFR-2, 1.01 µM against EGFR, and 1.94 µM against topoisomerase II. EGFR/VEGFR2-IN-13 induces cell cycle arrest and apoptosis in tumor cells. As an anticancer agent, EGFR/VEGFR2-IN-13 exhibits cytotoxicity against cancer cells. EGFR/VEGFR2-IN-13 can be used in research related to breast cancer, colon cancer, and liver cancer .

Cat. No.	Product Name

HY-L065

Traditional Chinese Medicine Active Compound Library	3,248 compounds
Chinese herbal therapy is an important part of Traditional Chinese Medicine (TCM). It has been used for centuries in China, where herbs are considered fundamental therapy for many acute and chronic conditions. Many studies indicated TCM exerted an overall regulatory effect via multi-component and multi-target network. Active components from Traditional Chinese Medicine possess many medicinal properties such as antioxidant, anti-cancer, and anti-bacterial effects, which makes it an important source of new drugs. Nearly 200 modern medicines have been developed either directly or indirectly from the plants used as medicines in China. For example, artemisinin, used in multidrug resistant malaria, was first isolated from the Chinese herb Artemisia annua L. Today, scientists continue to identify compounds in Chinese herbal remedies that may be useful in the development of new therapeutic agents applicable in Western medicine. MCE designs a unique collection of 3,248 active compounds of Chinese Herbal Medicines. MCE Traditional Chinese Medicine Active Compound Library is a useful tool for discovery new drugs from TCM.

Traditional Chinese Medicine Active Compound Library

3,248 compounds

Chinese herbal therapy is an important part of Traditional Chinese Medicine (TCM). It has been used for centuries in China, where herbs are considered fundamental therapy for many acute and chronic conditions. Many studies indicated TCM exerted an overall regulatory effect via multi-component and multi-target network. Active components from Traditional Chinese Medicine possess many medicinal properties such as antioxidant, anti-cancer, and anti-bacterial effects, which makes it an important source of new drugs. Nearly 200 modern medicines have been developed either directly or indirectly from the plants used as medicines in China. For example, artemisinin, used in multidrug resistant malaria, was first isolated from the Chinese herb Artemisia annua L. Today, scientists continue to identify compounds in Chinese herbal remedies that may be useful in the development of new therapeutic agents applicable in Western medicine.

MCE designs a unique collection of 3,248 active compounds of Chinese Herbal Medicines. MCE Traditional Chinese Medicine Active Compound Library is a useful tool for discovery new drugs from TCM.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N12586

Pheophytin a	Suaeda vermiculata Forssk. ex J.F.Gmel. Structural Classification Alkaloids Other Alkaloids Amaranthaceae Plants Source Classification	ERK Reactive Oxygen Species (ROS) COX PGE synthase STAT HCV HCV Protease
Pheophytin a is a multi-target inhibitor, anticancer agent, antioxidant and antiviral agent. Pheophytin a directly binds to and inhibits HCV-NS3/4A protease (IC₅₀=0.89 μM) to block viral replication. Pheophytin a also scavenges free radicals, reduces ferric ions, and exhibits cytotoxic activity against breast cancer cells. Pheophytin a effectively inhibits LPS-induced production of nitric oxide, prostaglandin E2, NOS2 and COX-2, as well as various pro-inflammatory cytokines, by downregulating the transcription levels of inflammatory mediators and blocking the ERK1/2 and STAT-1 pathways. In a low nerve growth factor environment, Pheophytin a also enhances ERK1/2 phosphorylation and synergistically promotes neurite outgrowth through MAPK pathway. Pheophytin a can be used to investigate the pathogenic mechanisms of diseases including chronic hepatitis C, sepsis, breast cancer and Alzheimer's disease .

Cat. No.	Product Name	Chemical Structure

HY-W751179

Midostaurin-13C6
Midostaurin- ¹³C₆ (PKC412- ¹³C₆) is the ¹³C-labeled Midostaurin (HY-10230). Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

Midostaurin-13C6

Midostaurin- ¹³C₆ (PKC412- ¹³C₆) is the ¹³C-labeled Midostaurin (HY-10230). Midostaurin (PKC412; CGP 41251) is an orally active, reversible multi-targeted protein kinase inhibitor. Midostaurin inhibits PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC₅₀s ranging from 22-500 nM . Midostaurin also upregulates endothelial nitric oxide synthase (eNOS) gene expression. Midostaurin shows powerful anticancer effects .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks